A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Treatment with risankizumab following inadequate response to secukinumab or ixekizumab was associated with improved disease severity, quality of life, and symptoms among patients with plaque psoriasis ...

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Q: I was just diagnosed with Type 2 diabetes. I feel like the doctor is expecting me to do his job! He loaded me down with a ...

Emissions Reduction Alberta (ERA) : The Government of Alberta and Natural Resources Canada just committed a combined $50M for ERA's new Strategic Energy Management for Industry (SEMI) program. They ...

ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net ...

Werewolf Therapeutics, Inc. (the "Company” or "Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data ...